Health Highlights: July 31, 2020
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
More Ball Games Postponed After Coronavirus Hits Phillies Staff
Two staff members of the Philadelphia Phillies have tested positive for the coronavirus, causing Major League Baseball to postpone this weekend's games with the Toronto Blue Jays, CBS News reported Thursday.
"Out of an abundance of caution, the Philadelphia Phillies' three-game weekend series with the Toronto Blue Jays, scheduled for Saturday, August 1st and Sunday, August 2nd at Citizens Bank Park, has been postponed," the league said in a statement.
The Phillies said that one of their coaching staff and a clubhouse staffer tested positive for COVID-19. "All activity at Citizens Bank Park has been canceled today and until further notice," the team said.
This latest postponement comes on the heels of an outbreak of the virus among the Miami Marlins. Over a dozen players and staff on the team tested positive for the virus after playing the Phillies last week, CBS reported.
MLB also postponed all Marlins games through Sunday and also postponed the Phillies-Yankees series scheduled for this week.
Commissioner Rob Manfred told reporters that team owners haven't thought about canceling or suspending the season.
"We expected we were going to have positives at some point in time," he said. "I remain optimistic that the protocols are strong enough that it will allow us to continue to play."
Former Presidential Candidate Herman Cain Dead From Coronavirus
Herman Cain, a former Republican presidential candidate, has died from coronavirus, CBS News reported Thursday. Cain, a right-wing media celeb, was 74.
On June 29, Cain was hospitalized with COVID-19. He knew "that this was going to be a rough fight" because he had survived cancer and was vulnerable because of his age and health, Dan Calabrese, the editor of Cain's website, posted Thursday morning, CBS reported.
Cain ran for president in 2011 but suspended his campaign after being accused of sexual harassment during his time as CEO of the National Restaurant Association. He denied the charges, CBS reported.
Cain had been president of Burger King before he became chairman and CEO of Godfather's Pizza.
Cain attended President Trump's rally in Tulsa, Okla., on June 20. He was photographed not wearing a face mask, but he did not come in contact with the president, CBS noted.
Cain is survived by a wife, Gloria, his children Melanie and Vincent, and grandchildren, according to CBS.
First U.S. Dog With COVID-19 Has Died
Buddy, a 7-year-old German shepherd, that was the first dog to test positive for the coronavirus in the United States, has died after being sick for three months, CNN reported Thursday.
Whether the dog died from the coronavirus or lymphoma isn't clear. Buddy got sick in April but it wasn't until May that a vet confirmed the animal was infected.
In June, the U.S. Department of Agriculture (USDA) confirmed this was the first dog to test positive for the coronavirus in the country, CNN noted.
Buddy's health continued to worsen. By July 11, the dog's owner told National Geographic, that the dog was throwing up clotted blood.
According to the USDA, less than 25 dogs and cats have been infected with coronavirus in this country.
But because there is no mandatory testing for animals in homes with people diagnosed with COVID-19, it's not known how many pets may be infected, CNN said.
"The second dog to test positive in the U.S., in Georgia, and the sixth dog, in South Carolina, have both died, for example, and their deaths were attributed to other conditions," National Geographic reported.
The U.S. Centers for Disease Control and Prevention has guidance for caring for a pet with COVID-19, but there's no reliable data on how the virus affects pets, CNN reported.
One-shot J&J COVID Vaccine Works in Monkeys
An experiential vaccine to protect against COVID-19 developed by Johnson & Johnson appears effective in monkeys, the New York Times reported Thursday.
This is the second vaccine that had promising results in monkeys reported this week, but whether they work in humans is the real test.
A human test is now underway in Europe and the United States. More than 30 human trials have been started testing coronavirus vaccines, but not until these trials are over in several months will we know if they work in people.
"This week has been good -- now we have two vaccines that work in monkeys," Angela Rasmussen, a virologist at Columbia University who was not involved in the studies, told the Times. "It's nice to be upbeat for a change."
These new results can't be used to speed trials in humans. "We just can't take shortcuts," she said.
The two vaccines work very differently.
The one by Moderna delivers messenger RNA into cells which causes an immune response to the virus. RNA vaccines have not yet been approved for use in people, the Times noted.
Moderna began Phase 3 trials on Monday, as did Pfizer.
The Johnson & Johnson vaccine activates the immune response by altering the virus.
A single shot of the vaccine was able to protect five out of six monkeys and the sixth had only low levels of the virus, the Times reports.
"The fact that we could protect with a single shot in animal models was quite a positive surprise to us," Dr. Paul Stoffels, the chief scientific officer of Johnson & Johnson, told the Times.
"It's exciting to see the number of platforms that are showing promise for a vaccine," Stacey Schultz-Cherry, a virologist at St. Jude Children's Research Hospital in Memphis who was not involved in any of the trials, told the paper.
Alzheimer's Brain Scans May Not Be Worth the Price
A study has failed to show that brain scans to check for Alzheimer's disease save health care costs for Medicare, the Associated Press reported Thursday.
The finding is from a $100 million study involving more than 25,000 Medicare patients.
Those who support Medicare coverage for the scans hope to show that they are beneficial even if they don't save money.
Diagnosing the disease can help families plan for the future even though there is no effective treatment or cure for Alzheimer's, researcher Dr. Gil Rabinovici of the University of California, San Francisco, told the AP.
A spokesman for the Centers for Medicare and Medicaid Services told the AP that the agency looks at all data on risks and benefits. A formal request would have to be filed for the agency to reconsider its 2013 decision to not cover the scans except for research and in special circumstances.
More than 5 million Americans have Alzheimer's, which can only be diagnosed after death.
PET brain can detect signs when patients are alive, but they cost $4,000 to $5,000 and insurers won't cover them because it's not known if they benefit patients.
For the study, nearly 12,700 people with dementia or mild cognitive impairment, were given scans and compared with Medicare patients not given scans.
Results from the first 4,000 participants suggested the scans diagnosed Alzheimer's and altered counseling or care in up to 60% of cases.
The study looked at whether the scans save money by decreasing hospitalizations and emergency room visits. The theory was that if a scan identifies that someone has Alzheimer's, caregivers can help prevent problems like patients not taking their medications.
But the goal of lowering hospitalizations by 10% in the year after the scan wasn't met. Rates of hospitalizations were 24% among patients scanned and 25% among those who weren't.
Among those scanned, however, fewer hospitalizations occurred for those with Alzheimer's, the AP reports.
Maria Carrillo, the Alzheimer's Association's chief science officer, told the AP that these findings suggest that caregivers "weren't panicking" when symptoms of Alzheimer's appeared and didn't rush to the hospital.
The results of the study were scheduled to be presented July 30 at the online Alzheimer's Association International Conference.
© 2020 HealthDay. All rights reserved.
Posted: July 2020
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.